Rapport Therapeutics Common Stock Buy Hold or Sell Recommendation
| RAPP Stock | 26.81 0.05 0.19% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Rapport Therapeutics Common is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Rapport Therapeutics Common within the specified time frame.Check out Rapport Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Rapport and provide practical buy, sell, or hold advice based on investors' constraints. Rapport Therapeutics Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
Execute Rapport Therapeutics Buy or Sell Advice
The Rapport recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Rapport Therapeutics Common. Macroaxis does not own or have any residual interests in Rapport Therapeutics Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Rapport Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Rapport Therapeutics Trading Alerts and Improvement Suggestions
| Rapport Therapeutics had very high historical volatility over the last 90 days | |
| Rapport Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (78.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rapport Therapeutics generates negative cash flow from operations | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: A Look At Rapport Therapeutics Valuation After FDA Clears Phase 3 Trial For RAP-219 |
Rapport Therapeutics Returns Distribution Density
The distribution of Rapport Therapeutics' historical returns is an attempt to chart the uncertainty of Rapport Therapeutics' future price movements. The chart of the probability distribution of Rapport Therapeutics daily returns describes the distribution of returns around its average expected value. We use Rapport Therapeutics Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Rapport Therapeutics returns is essential to provide solid investment advice for Rapport Therapeutics.
| Mean Return | 0.19 | Value At Risk | -6.77 | Potential Upside | 6.16 | Standard Deviation | 3.85 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Rapport Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Rapport Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Rapport Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Rapport Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Rapport stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 0.66 | |
σ | Overall volatility | 3.82 | |
Ir | Information ratio | 0.02 |
Rapport Therapeutics Volatility Alert
Rapport Therapeutics Common shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Rapport Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Rapport Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Rapport Therapeutics Fundamentals Vs Peers
Comparing Rapport Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Rapport Therapeutics' direct or indirect competition across all of the common fundamentals between Rapport Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Rapport Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Rapport Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Rapport Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Rapport Therapeutics to competition |
| Fundamentals | Rapport Therapeutics | Peer Average |
| Return On Equity | -0.23 | -0.31 |
| Return On Asset | -0.16 | -0.14 |
| Current Valuation | 776.64 M | 16.62 B |
| Shares Outstanding | 47.66 M | 571.82 M |
| Shares Owned By Insiders | 4.69 % | 10.09 % |
| Shares Owned By Institutions | 95.31 % | 39.21 % |
| Number Of Shares Shorted | 2.69 M | 4.71 M |
| Price To Book | 2.50 X | 9.51 X |
| EBITDA | (77.47 M) | 3.9 B |
| Net Income | (78.31 M) | 570.98 M |
| Total Debt | 1.48 M | 5.32 B |
| Book Value Per Share | 10.74 X | 1.93 K |
| Cash Flow From Operations | (64.83 M) | 971.22 M |
| Short Ratio | 6.60 X | 4.00 X |
| Earnings Per Share | (2.27) X | 3.12 X |
| Target Price | 52.25 | |
| Number Of Employees | 69 | 18.84 K |
| Market Capitalization | 1.28 B | 19.03 B |
| Total Asset | 314.93 M | 29.47 B |
| Retained Earnings | (123.75 M) | 9.33 B |
| Working Capital | 301.04 M | 1.48 B |
| Net Asset | 314.93 M |
Note: Disposition of 200 shares by Bredt David of Rapport Therapeutics at 27.4 subject to Rule 16b-3 [view details]
Rapport Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Rapport . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Rapport Therapeutics Buy or Sell Advice
When is the right time to buy or sell Rapport Therapeutics Common? Buying financial instruments such as Rapport Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Rapport Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run USD Crypto Fund Thematic Idea Now
USD Crypto Fund
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.